1
|
Nishimura JI, Soubret A, Arase N, Buatois S, Hotta M, Charoin JE, Ito Y, Sreckovic S, Takamori H, Bucher C, Ueda Y, Hernández-Sánchez J, Gotanda K, Jordan G, Shinomiya K, Ramos J, Kim JS, Panse J, de Latour RP, Röth A, Morii E, Schrezenmeier H, Isaka Y, Sica S, Kanakura Y, Yoon SS, Kinoshita T, Paz-Priel I, Sostelly A. Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors. Clin Pharmacol Ther 2023; 113:904-915. [PMID: 36660902 DOI: 10.1002/cpt.2851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 01/06/2023] [Indexed: 01/21/2023]
Abstract
Drug-target-drug complexes (DTDCs) are phenomena newly observed in patients who switch from the complement component 5 (C5) inhibitor eculizumab to crovalimab, a novel, anti-C5 antibody in development for paroxysmal nocturnal hemoglobinuria (PNH), because these agents bind to different C5 epitopes. In Part 3 of the four-part, phase I/II COMPOSER study, 19 patients with PNH switching from eculizumab received 1,000-mg crovalimab intravenously, then subcutaneous maintenance doses from Day 8 (680 mg every 4 weeks (q4w), 340 mg every 2 weeks, or 170 mg every week). Crovalimab exposure was transiently reduced, and size-exclusion chromatography and crovalimab-specific enzyme-linked immunosorbent assays revealed DTDCs in all 19 patients' sera. Additionally, self-limiting mild to moderate symptoms suggestive of type III hypersensitivity reactions occurred in two patients. Mathematical modeling simulations of DTDC kinetics and effects of dosing on DTDC size distribution using Part 3 data predicted that increased crovalimab concentrations could reduce the proportion of large, slow-clearing DTDCs in the blood. A simulation-guided, optimized crovalimab regimen (1,000 mg intravenously; four weekly, subcutaneous 340-mg doses; then 680 mg q4w from Day 29) was evaluated in Part 4. Confirming the model's predictions, mean proportions of large DTDCs in patients who switched from eculizumab to this optimized regimen decreased by > 50% by Day 22, and target crovalimab concentrations were maintained. No type III hypersensitivity reactions occurred in Part 4. Optimizing crovalimab dosing thus reduced the proportion of large DTDCs, ensured adequate complement inhibition, and may improve safety. Model-based dosing optimization to mitigate DTDC formation offers a useful strategy for patients switching to novel antibody treatments targeting soluble epitopes.
Collapse
Affiliation(s)
- Jun-Ichi Nishimura
- Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
| | - Antoine Soubret
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Noriko Arase
- Department of Dermatology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
| | - Simon Buatois
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Masaki Hotta
- Department of Medical Technology, Osaka University Hospital, Osaka, Japan
| | - Jean-Eric Charoin
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Yoshikazu Ito
- Department of Hematology, Tokyo Medical University Hospital, Tokyo, Japan
| | | | - Hiroyuki Takamori
- Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
| | - Christoph Bucher
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Yasutaka Ueda
- Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
| | | | | | - Gregor Jordan
- Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany
| | | | - Julia Ramos
- Genentech, Inc., South San Francisco, California, USA.,Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Jin Seok Kim
- Yonsei University College of Medicine, Severance Hospital, Seoul, Korea
| | - Jens Panse
- Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany
| | | | - Alexander Röth
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Eiichi Morii
- Department of Pathology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan
| | - Hubert Schrezenmeier
- Institute of Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen und University Hospital Ulm, Ulm, Germany
| | - Yoshitaka Isaka
- Department of Nephrology, Graduate School of Medicine, Faculty of Medicine, Osaka, Japan
| | - Simona Sica
- Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Yuzuru Kanakura
- Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.,Department of Hematology, Sumitomo Hospital, Osaka, Japan
| | | | - Taroh Kinoshita
- Yabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
| | - Ido Paz-Priel
- Genentech, Inc., South San Francisco, California, USA.,Gilead Sciences, San Francisco, California, USA
| | - Alexandre Sostelly
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.,Alnylam Pharmaceuticals, Basel, Switzerland
| |
Collapse
|
2
|
Asher J, Lemenuel-Diot A, Clay M, Durham DP, Mier-y-Teran-Romero L, Arguello CJ, Jolivet S, Wong DY, Kuhlbusch K, Clinch B, Charoin JE. Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLoS Comput Biol 2023; 19:e1010797. [PMID: 36608108 PMCID: PMC9876374 DOI: 10.1371/journal.pcbi.1010797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 01/25/2023] [Accepted: 12/07/2022] [Indexed: 01/09/2023] Open
Abstract
To aid understanding of the effect of antiviral treatment on population-level influenza transmission, we used a novel pharmacokinetic-viral kinetic transmission model to test the correlation between nasal viral load and infectiousness, and to evaluate the impact that timing of treatment with the antivirals oseltamivir or baloxavir has on influenza transmission. The model was run under three candidate profiles whereby infectiousness was assumed to be proportional to viral titer on a natural-scale, log-scale, or dose-response model. Viral kinetic profiles in the presence and absence of antiviral treatment were compared for each individual (N = 1000 simulated individuals); subsequently, viral transmission mitigation was calculated. The predicted transmission mitigation was greater with earlier administration of antiviral treatment, and with baloxavir versus oseltamivir. When treatment was initiated 12-24 hours post symptom onset, the predicted transmission mitigation was 39.9-56.4% for baloxavir and 26.6-38.3% for oseltamivir depending on the infectiousness profile. When treatment was initiated 36-48 hours post symptom onset, the predicted transmission mitigation decreased to 0.8-28.3% for baloxavir and 0.8-19.9% for oseltamivir. Model estimates were compared with clinical data from the BLOCKSTONE post-exposure prophylaxis study, which indicated the log-scale model for infectiousness best fit the observed data and that baloxavir affords greater reductions in secondary case rates compared with neuraminidase inhibitors. These findings suggest a role for baloxavir and oseltamivir in reducing influenza transmission when treatment is initiated within 48 hours of symptom onset in the index patient.
Collapse
Affiliation(s)
- Jason Asher
- Leidos, Reston, Virginia, United States of America
| | - Annabelle Lemenuel-Diot
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland
- * E-mail:
| | - Matthew Clay
- Leidos, Reston, Virginia, United States of America
| | | | | | | | - Sebastien Jolivet
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Diana Y. Wong
- Office of the Assistant Secretary for Preparedness and Response, U.S Department of Health and Human Services, Washington, District of Columbia, United States of America
| | | | - Barry Clinch
- Roche Products Ltd., Welwyn Garden City, United Kingdom
| | - Jean-Eric Charoin
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| |
Collapse
|
3
|
Hutchinson LG, Soubret A, Ribba B, Charoin JE, Phipps A, Peck R, Grimm O. Abstract 690: Optimization of biopsy scheduling in clinical studies of T cell bispecifics through an integrated modeling and simulation, digital pathology and machine learning approach. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In the context of cancer immunotherapy clinical trials, baseline and on-treatment tumor biopsies may provide important insight into whether a treatment is working as expected, and furthermore whether efficacy is anticipated. For tumor-retained antibodies that perturb the behaviour of immune cells, such as T cell bispecific antibodies (TCBs), spatial information derived from biopsy images may be particularly insightful. On-treatment biopsies in clinical trials are usually scheduled at a time point that is considered convenient for the study design and when therapeutic effects, such as T cell infiltration, are expected to be distinguishable in tumor tissue. To our knowledge, there have been no attempts to investigate optimal scheduling of on-treatment biopsy sample collection using quantitative approaches due to lack of clinical data at a sufficiently diverse range of time points.
Our integrated tissue pathology, disease modeling and machine learning workflow is designed to select the time point at which on-treatment biopsies could be most informative for making reliable predictions of response to treatment. Leveraging around 20 baseline and on-treatment digitized biopsy images from patients undergoing treatment with immune stimulating TCBs, we train a mathematical model to simulate tumor cell/T cell interactions in the tumor microenvironment. The mathematical model produces an enriched dataset of “virtual” biopsy images corresponding to predictions at intermediate time points. The virtual biopsies are evaluated based on their ability to predict treatment response.
Specific mechanisms of action of bispecific antibodies, such as upregulation of T cell activation and/or proliferation, are taken into account in the structure of the mathematical model. The model is tuned and validated using machine learning techniques, and a reserved “test” dataset comprising images that were not used to estimate model parameters is used to evaluate model performance. Our workflow has the potential to inform clinical study design by promoting a scientific basis for the selection of an on-treatment biopsy schedule. Future applications of this workflow include identification of tissue properties that may contribute to inter-individual variability, and simulations of novel doses and schedules for combinations of immune-modulating cancer therapies.
Citation Format: Lucy G. Hutchinson, Antoine Soubret, Benjamin Ribba, Jean-Eric Charoin, Alex Phipps, Richard Peck, Oliver Grimm. Optimization of biopsy scheduling in clinical studies of T cell bispecifics through an integrated modeling and simulation, digital pathology and machine learning approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 690.
Collapse
Affiliation(s)
| | | | | | | | - Alex Phipps
- 2Roche Innovation Center, Welwyn, United Kingdom
| | | | | |
Collapse
|
4
|
Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol 2010; 50:507-20. [PMID: 20179322 DOI: 10.1177/0091270009343931] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin receptor activator. C.E.R.A. is administered via intravenous (IV) and subcutaneous (SC) routes once every 2 weeks (Q2W) or once every 4 weeks (Q4W), respectively, to correct or maintain hemoglobin levels in chronic kidney disease (CKD) patients. Population models were specified to describe C.E.R.A. (PK) and hemoglobin (PD) concentrations over time, using data from 3 phase III, open-label, randomized, parallel-group, multicenter studies that examined IV or SC C.E.R.A. administration Q2W and Q4W in erythropoiesis-stimulating agent (ESA)-naive and ESA-treated patients. C.E.R.A. PK was described by a 1-compartment model: drug clearance = 0.75 L/d, volume of distribution = 4.72 L, and half-life = 105 hours in accordance with previous reported values. The PD model, a life span sequential PK/PD model, adequately described hemoglobin data. Dosing schedule, administration route, and study type did not affect drug-related PD parameters or system-specific parameters (eg, red blood cell life span). This model adequately described C.E.R.A.'s PK and PD properties according to C.E.R.A. posology, thus permitting simulations exploring alternative drug administration scenarios. It supports use of C.E.R.A. IV and SC; Q2W for anemia correction in ESA-Naïve CKD patients and monthly administration in the hemoglobin maintenance phase.
Collapse
Affiliation(s)
- Pascal Chanu
- PharmD, Pharsight - A Certara Company, Lyon, France.
| | | | | | | | | |
Collapse
|
5
|
Kaeser B, Charoin JE, Gerber M, Oxley P, Birnboeck H, Saiedabadi N, Banken L. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int J Clin Pharmacol Ther 2005; 43:154-62. [PMID: 15792400 DOI: 10.5414/cpp43154] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVES This study was designed to assess the bioequivalence between the commercial 250 mg nelfinavir tablet and the new 625 mg nelfinavir tablet (Roche) which was developed to reduce the daily pill burden for patients from 10 to 4 tablets in a nelfinavir 1250 mg twice daily regimen. METHODS A total of 52 healthy male subjects were enrolled in this randomized four-period crossover study to receive single oral doses of 1250 mg nelfinavir administered as five commercial 250 mg tablets (reference formulation) and as two new 625 mg tablets (test formulation). Each of the two formulations were taken after an overnight fast and immediately after intake of a standard breakfast (820 kcal) on separate occasions. Blood samples were collected pre-dose and at appropriate intervals after drug administration. Plasma concentrations of nelfinavir and its main metabolite M8 were assayed by a validated LC-MS/ MS assay and the pharmacokinetics of nelfinavir and M8 were derived using standard non-compartmental analysis. RESULTS The primary parameters for bioequivalence testing were the logarithmically transformed AUC(0-inf) and C(max) of nelfinavir taken from 50 subjects who completed all four treatments. Bioequivalence was accepted if the 90% confidence interval (CI) was contained entirely in the equivalence region (80%, 125%). In the fed state, this criterion was met for AUC (effect ratio = 95%; CI = 87%, 103%) and Cmax (effect ratio = 101%; CI = 94%, 109%) and bioequivalence of the two treatments could be concluded. In the fasted state, AUC clearly failed to meet the bioequivalence criteria (effect ratio = 73%; CI = 59%, 90%) and Cmax was borderline outside the lower acceptance region (effect ratio = 97%; CI = 79.6%, 118%). Therefore, bioequivalence could not be concluded under fasted condition. Food increased the systemic exposure to nelfinavir (as reflected by comparison of the logarithmically transformed AUC(0-inf) values under fed and fasted conditions) by six- and eight-fold after dosing with the 250 mg and the 625 mg tablet, respectively. CONCLUSIONS Bioequivalence of the new 625 mg nelfinavir tablet relative to the commercial 250 mg tablet, at a dose of 1250 mg, was confirmed in the fed state but not under fasted conditions. As nelfinavir is recommended to be taken with food, the new tablet is well-suited to decrease the daily pill burden for patients on a nelfinavir twice daily regimen and to enhance patient's compliance and adherence.
Collapse
Affiliation(s)
- B Kaeser
- Department of Clinical Pharmacology, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
| | | | | | | | | | | | | |
Collapse
|